Bucindolol

Bucindolol

Bucindolol is a non-selective beta blocker and beta-1 adrenergic receptor antagonist that was developed to treat hypertension and heart failure. It is unique among beta blockers for its additional properties as a beta-2 adrenergic receptor antagonist and alpha-1 adrenergic receptor antagonist.

Pharmacology

Bucindolol is a beta blocker, a class of drugs that work by blocking the action of epinephrine (adrenaline) on the beta receptors in the heart and blood vessels. This slows the heart rate and reduces the force of heart contractions, which lowers blood pressure and reduces the heart's demand for oxygen. Bucindolol is non-selective, meaning it blocks both beta-1 and beta-2 receptors.

In addition to its beta-blocking activity, Bucindolol also has mild vasodilating properties due to its antagonism of alpha-1 adrenergic receptors. This can help to further lower blood pressure.

Clinical Use

Bucindolol was developed for the treatment of hypertension (high blood pressure) and heart failure. In heart failure, it works by reducing the heart's workload and helping the heart to pump more efficiently. In hypertension, it helps to lower blood pressure by reducing the force and rate of heart contractions.

Side Effects

Like all medications, Bucindolol can cause side effects. Common side effects include bradycardia (slow heart rate), hypotension (low blood pressure), fatigue, and dizziness. Less common side effects can include depression, insomnia, and shortness of breath.

Development and Approval

Bucindolol was developed by a pharmaceutical company called Bristol-Myers Squibb. However, it was not approved by the Food and Drug Administration (FDA) in the United States due to concerns about its side effect profile. Despite this, it has been approved for use in other countries.

See Also

• Beta blocker
• Hypertension
• Heart failure

‎